Risk stratification of TP53^mut MN using CIT analysis. (A) The median OS for patients with TP53^mut MN was 8 months. (B) The median OS was progressively shorter with increasing blast percentage categories. (C) Patients with a TP53^mut VAF >8% had significantly poorer median OS compared with those with a VAF ≤8%. (D) CIT analysis identified the following 4 distinct risk groups with distinct survival: MDS-LB, MDS-EB1 or -EB2 or AML with VAF <10%, MDS-EB1 or -EB2 with VAF ≥10%, and AML VAF ≥10%. 95% CI, 95% confidence interval.